Skip to main content
. 2023 Nov 24;10(2):e001074. doi: 10.1136/lupus-2023-001074

Table 5.

Adverse events after introduction of telitacicept therapy

Adverse events N (%)
Any adverse event after start of therapy, n (%) 19 (26.39)
Serious adverse events, n (%) 0 (0.0)
Infection, n (%) 17 (23.6)
 Upper respiratory tract infection, n (%) 5 (6.9)
 Urinary tract infection, n (%) 7 (9.7)
 Herpes zoster, n (%) 1 (1.4)
 Herpes simplex, n (%) 2 (2.7)
 Cytomegalovirus, n (%) 2 (2.7)
Gastrointestinal disorders, n (%) 2 (2.7)
 Diarrhoea, n (%) 1 (1.4)
Leucopenia, n (%) 0 (0)